Skip to main content
GANX
NASDAQ Life Sciences

FDA Clears Gain Therapeutics' Parkinson's Drug GT-02287 for Phase 2 Study

Tom Rudovsky · Reported by Dow Jones Newswires
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$2.15
Mkt Cap
$84.455M
52W Low
$1.41
52W High
$4.34
52W Position info
52% above low
Off High info
50% below high
Rel. Volume info
1.4× avg
Market data snapshot near publication time

GANX sits 52% above its 52-week low of $1.41.

Summary

Gain Therapeutics received FDA clearance for its Investigational New Drug (IND) application for GT-02287, allowing the Parkinson's disease treatment to advance into Phase 2 development. This positive regulatory step follows the interim positive Phase 1b data for GT-02287 reported on May 26th. Advancing a drug into Phase 2 is a critical de-risking milestone for a clinical-stage biotech, providing a much-needed positive development given the company's recent 10-Q filing which highlighted significant financial challenges and a going concern warning.

At the time of this announcement, GANX was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.5M. The 52-week trading range was $1.41 to $4.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


Price Chart

Share this article

Copied!

GANX - Latest Insights

GANX
Oct 01, 2026, 9:28 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $1.74
Real-time Price: $1.03 info
Change: -$0.715 (-41%) info
Market Cap: $44.953M info
GANX
Oct 01, 2026, 9:16 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.75
Real-time Price: $1.03 info
Change: -$0.7275 (-42%) info
Market Cap: $44.953M info
GANX
Aug 11, 2026, 4:07 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $2.00
Real-time Price: $1.03 info
Change: -$0.9776 (-49%) info
Market Cap: $44.953M info
GANX
Aug 11, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.06
Real-time Price: $1.03 info
Change: -$1.04 (-50%) info
Market Cap: $44.953M info
GANX
Jul 16, 2026, 7:53 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.68
Real-time Price: $1.03 info
Change: -$0.655 (-39%) info
Market Cap: $44.953M info